Back of the envelope: Mr. Berman continued, "Th
Post# of 11802
(Total Views: 377)
Posted On: 10/18/2017 10:28:15 AM
Back of the envelope:
Mr. Berman continued, "There are approximately 28 million glucometers in use worldwide, and it is growing. Even if we benchmark with a static growth rate, DECN can still forecast a 6% market share for GenPrecis!™, by 2022. With the average usage of three test strips per day ($1.20), we believe that GenPrecis!™, could generate $155 million annually in the traditional Type II marketplaces, and an additional $110 million annually in Type 1, Gestational, and Type 1.5 marketplaces. Net profit margins are expected to be in excess of 20%.
$265M x 20% / 100M shares x 14 P/E ratio = $7.42 share price.
And that is just one of their products.
Wait at your own peril.
Mr. Berman continued, "There are approximately 28 million glucometers in use worldwide, and it is growing. Even if we benchmark with a static growth rate, DECN can still forecast a 6% market share for GenPrecis!™, by 2022. With the average usage of three test strips per day ($1.20), we believe that GenPrecis!™, could generate $155 million annually in the traditional Type II marketplaces, and an additional $110 million annually in Type 1, Gestational, and Type 1.5 marketplaces. Net profit margins are expected to be in excess of 20%.
$265M x 20% / 100M shares x 14 P/E ratio = $7.42 share price.
And that is just one of their products.
Wait at your own peril.
(1)
(0)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼